drugset
drugset / Trial / NCT03430583

Evaluation of Fontan-associated Hepatic Stiffness and the Efficacy of Udenafil in Reducing Liver Stiffness

NCT03430583 ↗

Phase 3 Completed 88 enrolled Mezzion Pharma Co. Ltd National Heart, Lung, and Blood Institute (NHLBI) · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

A study to evaluate the efficacy of MZ101 therapy in reducing liver stiffness.

Timeline

Start
2018-02-20
Primary completion
2020-09-15
Completion
2020-09-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Udenafil Small molecule 87.5 mg —

Indications

univentricular cardiopathy